NVGN - Novogen Limited

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.9459
-0.1041 (-3.4131%)
At close: 2:59PM EDT
Stock chart is not supported by your current browser
Previous Close3.0500
Open2.9597
Bid2.8000 x 1000
Ask9.5000 x 200
Day's Range2.9459 - 2.9597
52 Week Range0.7000 - 3.8200
Volume706
Avg. Volume7,466
Market Cap14.57M
Beta1.05
PE Ratio (TTM)-1.34
EPS (TTM)-2.2
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.86
Trade prices are not sourced from all markets
  • ACCESSWIRElast month

    Edison Issues ADR Update on Novogen (NVGN)

    LONDON, UK / ACCESSWIRE / September 11, 2017 / Novogen (NASDAQ: NVGN) is on track to commence a Phase II trial of GDC-0084 in glioblastoma in Q4 CY17, in line with previous guidance. It plans to meet with ...

  • PR Newswire2 months ago

    Australian cancer specialists may hold key to next advancement in ovarian cancer treatment

    SYDNEY, Aug. 30, 2017 /PRNewswire/ -- Three leading Australian cancer treatment centres are at the forefront of a drug trial that could see the next major advancement in ovarian cancer therapy. Flinders Medical Centre in South Australia and Westmead Hospital in Sydney are also participating, along with leading US hospitals Peggy and Charles Stephenson Cancer Centre, and Mary Crowley Cancer Research Centre. "We've seen massive developments in other types of cancer but ovarian cancer has remained a challenge and, despite it being an unforgiving disease for women, treatment options have fallen behind as money and research are focused elsewhere," Associate Professor Coward said.

  • PR Newswire2 months ago

    GDC-0084 Progress Update: On Track for Phase II Commencement in 2017

    NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on progress with its clinical-stage drug development candidate, GDC-0084. GDC-0084 was in-licensed from Genentech, Inc in October 2016, after completion of a phase I clinical trial in advanced glioma.

  • PR Newswire2 months ago

    GDC-0084 Progress Update: On Track for Phase II Commencement in 2017

    NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on progress with its clinical-stage drug development candidate, GDC-0084. GDC-0084 was in-licensed from Genentech, Inc in October 2016, after completion of a phase I clinical trial in advanced glioma.

  • PR Newswire2 months ago

    Board Review of Business Operations and Governance

    NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on a review of business operations recently completed by the Board and management team. The review was initiated following appointment of Iain Ross as Chairman on 8 June 2017, and has involved an extensive process of consultation with shareholders and investors.

  • PR Newswire2 months ago

    Board Review of Business Operations and Governance

    NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on a review of business operations recently completed by the Board and management team. The review was initiated following appointment of Iain Ross as Chairman on 8 June 2017, and has involved an extensive process of consultation with shareholders and investors.

  • PR Newswire2 months ago

    Progress Update on Cantrixil(TM) (TRXE-002-1) Development

    NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on progress with its clinical-stage development candidate, Cantrixil (TRXE-002-1). Novogen commenced a phase I clinical trial of Cantrixil in ovarian cancer in December 2016.

  • PR Newswire2 months ago

    Progress Update on Cantrixil(TM) (TRXE-002-1) Development

    NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on progress with its clinical-stage development candidate, Cantrixil (TRXE-002-1). Novogen commenced a phase I clinical trial of Cantrixil in ovarian cancer in December 2016.

  • Democrats found a way to speak Trump's language in pharma debate
    Yahoo Finance7 months ago

    Democrats found a way to speak Trump's language in pharma debate

    The members of congress introduced a bill related to the talk last week. A quartet of Democratic members of Congress introduced a bill last week in harmony with President Donald Trump’s campaign promises of lowering prescription drug costs. Entitled the Improving Access to Affordable Prescription Drugs Act, the 128-page bill aims to overhaul what many view as a broken system that has seen bipartisan outrage over skyrocketing prices.

  • Benzinga7 months ago

    Novogen Receives $4.4M R&D Tax Rebate

    Novogen Ltd (NASDAQ: NVGN ) is pleased to confirm receipt of $4.4m from the Australian Taxation Office under the R&D Tax Incentive Program for the financial year ending 30 June 2016. These funds will be ...

  • PR Newswire7 months ago

    Transformation to a Clinical Stage Organisation Leads to Changes in Management Structure

    - Recent in-licensing of GDC-0084 and advancement of Cantrixil to phase I represent transformation of Novogen to clinical-stage organisation; recent appointments of Chief Medical Officer and Head of CMC ...

  • PR Newswire7 months ago

    Transformation to a Clinical Stage Organisation Leads to Changes in Management Structure

    - Recent in-licensing of GDC-0084 and advancement of Cantrixil to phase I represent transformation of Novogen to clinical-stage organisation; recent appointments of Chief Medical Officer and Head of CMC ...

  • PR Newswire7 months ago

    Novogen Awarded Grant of up to A$3m by Australian Federal Government for Novel Drug Discovery Program

    Funds will be applied to development of a next-generation anti-tropomyosin program, intended to provide potential new therapies for cancer. NASDAQ: NVGN) is pleased to announce that it has been awarded a grant of up to A$3m over three years under the Cooperative Research Centre Project (CRC-P) scheme managed by the Australian Department of Industry Innovation and Science (DIIS). The grant has been awarded to fund development of a next-generation anti-tropomyosin program, which is intended to provide potential new therapies for cancer.

  • PR Newswire7 months ago

    Novogen Awarded Grant of up to A$3m by Australian Federal Government for Novel Drug Discovery Program

    Funds will be applied to development of a next-generation anti-tropomyosin program, intended to provide potential new therapies for cancer. NASDAQ: NVGN) is pleased to announce that it has been awarded a grant of up to A$3m over three years under the Cooperative Research Centre Project (CRC-P) scheme managed by the Australian Department of Industry Innovation and Science (DIIS).

  • Benzingalast year

    Novogen Licenses Phase II-ready Molecule from Genentech for Development in Glioblastoma for $5M Upfront , Plus Milestones

    Novogen Ltd (NASDAQ: NVGN ) today announced that it has entered into a worldwide licensing agreement with Genentech, a member of the Roche Group (OTC: RHHBY ), to develop and commercialise GDC-0084, a ...